Author
Jack Stone
Bio: Jack Stone is an academic researcher from University of Bristol. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 13, co-authored 35 publications receiving 1788 citations.
Papers
More filters
••
TL;DR: A global multistage systematic review of sharing of equipment used for injecting drug use (IDU) identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa.
951 citations
••
Columbia University1, University of Malaya2, Yale University3, Central European University4, Johns Hopkins University5, RTI International6, University of California, San Francisco7, University of British Columbia8, Centro de Investigación y Docencia Económicas9, University of California, San Diego10, University of the Andes11, Human Rights Watch12, University of Uyo13, University of Bristol14, Charles University in Prague15
TL;DR: The Johns Hopkins-Lancet Commission on Drug Policy and Health as mentioned in this paper examined the emerging scientific evidence on public health issues arising from drug control policy and to inform and encourage a central focus on health evidence and outcomes in drug-policy debates, such as the important deliberations of the 2016 UNGASS on drugs.
365 citations
••
TL;DR: Opioid agonist treatment can be highly effective in reducing illicit opioid use and improving multiple health and social outcomes, by reducing overall mortality and key causes of death, including overdose, suicide, HIV, hepatitis C virus, and other injuries.
347 citations
••
TL;DR: Interventions that reduce incarceration itself and effectively intervene with prisoners to screen, diagnose, and treat addiction and HIV, hepatitis C virus, and tuberculosis are urgently needed to stem the multiple overlapping epidemics concentrated in prisons.
204 citations
••
TL;DR: Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recently injected drug use, there is wide variation among countries and regions.
Abstract: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional, and country-levels. Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV. There are an estimated 6.1 million [95% uncertainty interval (UI) 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI 1.0-2.1), Eastern Europe (1.5 million, UI 0.7-2.4), and North America (1.0 million, UI 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI 11.7-56.7), Latin America (22.0%, UI 15.3-30.4), and Eastern Europe (17.9%, UI 8.2-30.9). Although globally about forty percent of people with recent injecting drug use are living with hepatitis C virus (HCV) and almost nine percent of all HCV infections globally occur among people with recent injecting drug use, there is wide variation among countries and regions. National Drug and Alcohol Research Centre, UNSW Sydney; Australian National Health and Medical Research Council; John C Martin Foundation.
168 citations
Cited by
More filters
••
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
2,491 citations
••
TL;DR: A global multistage systematic review of sharing of equipment used for injecting drug use (IDU) identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa.
951 citations
••
TL;DR: The aim of this study was to provide evidence that palliative care and pain relief research should be considered as a continuum of treatment for patients with life-threatening illnesses.
683 citations